Diabetic neuropathy

Postgraduate Medical Journal

Volumn 82, Issue 964, 2006, Pages 95-100

  Bansal, V ^a   Kalita, J ^a   Misra, U K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE INHIBITOR; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; CARNITINE; CISAPRIDE; DEXTROMETHORPHAN; DULOXETINE; FLUDROCORTISONE; FLUPHENAZINE; GABAPENTIN; IBUPROFEN; LAMOTRIGINE; METOCLOPRAMIDE; METRONIDAZOLE; MEXILETINE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROTEIN TYROSINE KINASE A; RECOMBINANT NERVE GROWTH FACTOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; COFFEE; CRANIAL NERVE; DIABETIC NEUROPATHY; DIARRHEA; ERECTILE DYSFUNCTION; FLUID INTAKE; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; LIMB; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUSCLE ATROPHY; NERVE CONDUCTION; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; QUANTITATIVE DIAGNOSIS; REVIEW; RISK FACTOR; SALT INTAKE; SENSORY NERVE; STOMACH DISEASE; SYMPTOMATOLOGY; THORAX; UNSPECIFIED SIDE EFFECT;

ALDEHYDE REDUCTASE; ANTIOXIDANTS; AUTONOMIC NERVOUS SYSTEM DISEASES; CHRONIC DISEASE; DIABETIC NEUROPATHIES; HUMANS; NOOTROPIC AGENTS; PAIN; RISK FACTORS; THIOCTIC ACID;

EID: 33144474834     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.036137     Document Type: Review

References (50)

1. Sadikot SM, Nigam A, Das S, et al. The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 2004;66:301-7.
2. Pickup J, Wilham G. Epidemiology of diabetes. In: Guikshank K, ed. Textbook of diabetes. New York: Blackwell Science, 1991.
3. Bajaj M, Banerji MA. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian Indian epidemic. Curr Diab Rep 2004;4:213-18.
4. Ashok S, Ramu M, Deepa R, et al. Prevalence of neuropathy in type 2 diabetes patients attending diabetes center in South India. J Assoc Physicians India 2002;50:546-50.
5. Levitt NS, Stansberry KB, Wychanck S, et al. Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM. Diabetes Care 1996;19:751-4.
6. Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993;10:820-4.
7. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973 (third and last part). Diabetes Metab 1977;3:245-56.
8. Dyck PJB, Sinnreich M. Diabetic Neuropathies. Continuum 2003;9:19-34.
9. Oh SJ. Clinical electromyography: nerve conduction studies. In: Nerve conduction in polyneuropathies. Baltimore: Williams and Wilkins, 1993:579-91.
10. Low P, Dotson R. Symptom treatment of painful neuropathy. JAMA 1998;280:1863-4.
11. Tesfaye S, Malik R, Harris N, et al. Arterio venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycemic control (insulin neuritis). Diabetologia 1996;39:329-35.
12. Van Heel DA, Levitt NS, Winter TA. Diabetic neuropathic cachexia-the importance of positive recognition and early nutritional support. Int J Clin Pract 1998;52:591-2.
13. Sumner C, Sheth S, Griffin J, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:108-11.
14. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001;24:1225-8.
15. Asbury AK. Proximal diabetic neuropathy. Ann Neurol 1977;2:179-80.
16. Dyck PJ, Winderbank AJ. Diabetic and non diabetic lumbosacral radiculoplexus neuropathies. New insights into pathophysiology and treatment. Muscle Nerve 2002;25:477-91.
17. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52:1053-61.
18. Pascoe MK, Low PA, Windebank AJ, et al. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997;72:1123-32.
19. Brittand ST, Young RJ, Sharma AK, et al. Acute and remitting diabetic polyneuropathy: a comparison of peripheral nerve fibre pathology. Pain 1992;48:361-70.
20. Milicevic Z, Newlon PG, Pittenger GL, et al. Anti-ganglioside GM1 antibody and distal symmetric 'diabetic polyneuropathy' with dominant motor features. Diabetologia 1997;40:1364-5.
21. Sharma K, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002;59:758-65.
22. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing. Neurology 2003;602:898-906.
23. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996;47:1042-8.
24. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003;46:683-8.
25. Consensus statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetic association, American Academy of Neurology. Diabetes Care 1988;11:592-7.
26. Dyck PJ. Detection, characterization and staging of polyneuropathy: assessed in diabetes. Muscle Nerve 1988;11:21-32.
27. Herman WH, Kennedy L. For the GOAL AIC study group. Physician perception of neuropathy in a large diabetes type 2 populations (GOAL AIC study) confirms under diagnosis of neuropathy in everyday clinical practice. Diabetologia 2003;46(suppl 2):A71.
28. Arezzo JC. The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Comm 1997;21:13-22.
29. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:89-94.
30. Venes A, Malik RA, Lye RH, et al. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy. Diabet Med 1991;8:917-21.
31. DCCT Research group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
32. UK Prospective Diabetes study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPD S38. BMJ 1998;317:703-13.
33. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
34. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50.
35. Didangelos TP, Karamitsos DT, Athyros VG, et al. Effect of Aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy. J Diabetes Complications 1998;12:201-7.
36. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-91.
37. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7 month multicentre randomized controlled trial (ALADIN III study). ALADIN III study group. Alpha-lipoic acid in diabetic neuropathy. Diabetes Care 1999;22:1296-301.
38. Keen H, Payan J, Allowi J, et al. Treatment of diabetic neuropathy with γ Linolenic acid. Diabetes Care 1993;16:8-15.
39. Sima AAF, Calvani M, Mehra M, et al. Acetyl L Carnitine improves pain, nerve regeneration and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care 2005;28:96-101.
40. Apfel SC, Kessler JA. Neurotropic factors in the therapy of peripheral neuropathy. Baillieres Clinical Neuropathy 1995;4:593-606.
41. Vinik AI. Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve growth factor (rh NGF). Diabetes 1999;48:A54-5.
42. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-92.
43. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Library. Issue 3. Oxford: Update Software, 2000.
44. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
45. Said G, Bigo A, Ameri A, et al. Uncommon early onset neuropathy in diabetic patients. J Neurol 1998;245:61-8.
46. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; May 28 (Epub ahead of print).
47. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311:1047-52.
48. Vinik A, Pittenger G, Anderson A, et al. Topiramate improves C fibre neuropathy and features of dysmetabolic syndrome in type 2 diabetes mellitus. Diabetes 2003;52(suppl 1):A130.
49. Cohen KL, Harris S. Efficacy and safety of non steroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987;147:1442-4.
50. Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy. Lancet 1990;336:449.